BRAF gene alterations are present in around 9% of CRC patients [168], and discoveries on a bench platform put a rationale and stimulated clinical trials’ design where metastatic CRC patients with BRAF V600E-mutated tumors underwent an overall survival benefit and higher response rate from concomitant treatment with BRAFi and MEKi along with anti-EGFR antibody [169]. Here, EGFR is linked to colorectal carcinoma.